Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
Bortezomib can be used to successfully treat acute kidney injury in the renal transplant allograft due to light chain cast nephropathy from recurrent multiple myeloma.
Dept of Medicine, Division of Nephrology and Transplant, University of Alabama at Birmingham, USA.
Vineeta
V
Kumar
Stephanie
S
Elkins
Robert S
RS
Gaston
Mary B
MB
Prendergast
Vishnu
V
Reddy
William J
WJ
Cook
Paul W
PW
Sanders
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D001706:Biopsy; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D019520:Living Donors; D009101:Multiple Myeloma / Q000150:complications*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D053668:Syndecan-1 / Q000032:analysis; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D001897:Boronic Acids; D007145:Immunoglobulin kappa-Chains; D007166:Immunosuppressive Agents; D011480:Protease Inhibitors; D011719:Pyrazines; D053668:Syndecan-1; D000074323:Alemtuzumab; D000069286:Bortezomib; D009173:Mycophenolic Acid; D016559:Tacrolimus